SCHEMBL7965165

SCHEMBL7965165

CCOc1cc(/C=N/NC(=O)C(OC)c2ccc(Cl)cc2)cc(Br)c1OC

nearest known ligand 0.73

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.57
POLB P06746 1/20 0.52
MAPK1 P28482 1/20 0.52
HSD17B10 Q99714 1/20 0.52
LMNA P02545 1/20 0.52
MAPT P10636 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7974688 0.91
SCHEMBL7961336 0.91 GAA (0.59) GAAPOLB
SCHEMBL7971480 0.85 GAA (0.66) GAALMNAMAPT
SCHEMBL7962692 0.84
SCHEMBL13491767 0.84
SCHEMBL7961035 0.83
SCHEMBL7961565 0.82
SCHEMBL7974683 0.81
SCHEMBL7961337 0.78 TRPM5 (0.59) GAAHSD17B10
SCHEMBL7962242 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180118711-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION 2018-05-03 US disclosed
US-9783521-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2017-10-10 US disclosed
US-20140038951-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2014-02-06 US disclosed
US-8377930-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2013-02-19 US disclosed
US-8377930-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2013-02-19 US disclosed
WO-2010017236-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2010-02-11 WO disclosed
US-20100035872-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2010-02-11 US disclosed
US-20100035872-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118711-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A GAA 64/4885POLB 770/4885MAPK1 3742/4885
US-20140038951-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A GAA 64/4885POLB 770/4885MAPK1 3742/4885
US-20100035872-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A GAA 64/4885POLB 770/4885MAPK1 3742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.